Cti Biopharma Corp patents expiration
1. Vonjo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8153632 | CTI BIOPHARMA CORP | Oxygen linked pyrimidine derivatives |
Jan, 2029
(4 years from now) | |
| US8980873 | CTI BIOPHARMA CORP | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt |
Mar, 2030
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9573964 | CTI BIOPHARMA CORP | Oxygen linked pyrimidine derivatives |
May, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-397) | Feb 28, 2029 |
| New Chemical Entity Exclusivity(NCE) | Feb 28, 2027 |
Drugs and Companies using PACRITINIB CITRATE ingredient
NCE-1 date: 28 February, 2026
Market Authorisation Date: 28 February, 2022
Treatment: Treatment of myelofibrosis with pacritinib; Use of pacritinib for inhibiting janus associated kinase 2(jak2)
Dosage: CAPSULE;ORAL
More Information on Dosage
VONJO family patents
